Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability
Authors' conclusion
These findings demonstrate that treatment with zoledronic acid in acute SCI attenuates losses in proximal femoral strength, which may reduce the risk of hip fractures across patients with varying degrees of ambulatory abilities.
Study context
- Population
- Individuals in the acute stage of spinal cord injury (SCI)
- Participants
- 29 vs 30
- Comparison
- Zoledronic acid vs placebo in acute SCI
- Zoledronic acidn = 29
- Placebon = 30reference
- Primary endpoint
- Change in CT-based finite element-predicted proximal femoral strength
- Follow-up
- 12 months
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Reduction in FE-predicted proximal femoral strength
Zoledronic acid
9.6
mean · SD 17.9 · %
Placebo
24.6
mean · SD 24.5 · %
P = 0.007
Further findings
Computed tomography (CT) measurements of trabecular and cortical bone at femoral neck and trochanteric region · 12 months
- Strength differences explained by reductions in trabecular bone
- P < 0.001
- Strength differences explained by reductions in cortical bone
- P ≤ 0.021
Influence of ambulation ability
- Ambulation ability influenced select trabecular and cortical parameters; no detectable impact on finite element (FE)-predicted bone strength
Original publication
Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability. Osteoporos Int. Published 8 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →